Drug import bill sidetracked as food safety measure advances ahead of health reform freight train
This article was originally published in The Gold Sheet
The House Energy and Commerce Committee has sidetracked drug and device import legislation to concentrate on food safety in the short window before healthcare reform dominates its agenda. Observers are left wondering when the committee will get around to advancing the non-food aspects of the Food and Drug Globalization Act it reintroduced earlier this year. Some of those provisions, like registration and fees for post-approval inspections of overseas drug manufacturing facilities, were a high priority in the months after last year's heparin fiasco. The committee June 17 marked up its Food Safety Enhancement Act, H.R. 2749, which incorporates food-related provisions from the tabled FDAGA, and rushed it on for consideration by the full House. "It seems like drug safety and medical devices will be worked in the near future," a Dingell spokesman assured "The Gold Sheet." However, healthcare reform legislation looms. "Clearly, it is a crowded calendar," the spokesman noted, "but this is something all the members want dealt with as soon as possible.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.